Orphanet Journal of Rare Diseases (Jan 2012)

Clinical expression of Menkes disease in females with normal karyotype

  • Møller Lisbeth,
  • Lenartowicz Malgorzata,
  • Zabot Marie-Therese,
  • Josiane Arnaud,
  • Burglen Lydie,
  • Bennett Chris,
  • Riconda Daniel,
  • Fisher Richard,
  • Janssens Sandra,
  • Mohammed Shehla,
  • Ausems Margreet,
  • Tümer Zeynep,
  • Horn Nina,
  • Jensen Thomas G

DOI
https://doi.org/10.1186/1750-1172-7-6
Journal volume & issue
Vol. 7, no. 1
p. 6

Abstract

Read online

Abstract Background Menkes Disease (MD) is a rare X-linked recessive fatal neurodegenerative disorder caused by mutations in the ATP7A gene, and most patients are males. Female carriers are mosaics of wild-type and mutant cells due to the random X inactivation, and they are rarely affected. In the largest cohort of MD patients reported so far which consists of 517 families we identified 9 neurologically affected carriers with normal karyotypes. Methods We investigated at-risk females for mutations in the ATP7A gene by sequencing or by multiplex ligation-dependent probe amplification (MLPA). We analyzed the X-inactivation pattern in affected female carriers, unaffected female carriers and non-carrier females as controls, using the human androgen-receptor gene methylation assay (HUMAR). Results The clinical symptoms of affected females are generally milder than those of affected boys with the same mutations. While a skewed inactivation of the X-chromosome which harbours the mutation was observed in 94% of 49 investigated unaffected carriers, a more varied pattern was observed in the affected carriers. Of 9 investigated affected females, preferential silencing of the normal X-chromosome was observed in 4, preferential X-inactivation of the mutant X chromosome in 2, an even X-inactivation pattern in 1, and an inconclusive pattern in 2. The X-inactivation pattern correlates with the degree of mental retardation in the affected females. Eighty-one percent of 32 investigated females in the control group had moderately skewed or an even X-inactivation pattern. Conclusion The X- inactivation pattern alone cannot be used to predict the phenotypic outcome in female carriers, as even those with skewed X-inactivation of the X-chromosome harbouring the mutation might have neurological symptoms.